Introduction
The growing worldwide burden of coronary artery disease (CAD) mandates the development and implementation of effective population-based interventions for primary and secondary prevention. A major limitation of one approach, coronary revascularization, is that it embraces a common response of many in the medical community, that is, the use of new technologies as a first-line strategy to stabilize overt cardiovascular disease. Moreover, coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI) have been largely unsuccessful in halting and reversing the epidemic. The escalating number of initial and repeat revascularizations has taught us a sobering lesson: the vessels used to bypass severely stenotic coronary arteries may close; symptoms may reappear; unbypassed arteries that previously did not contain an obstruction can experience abrupt plaque rupture and occlusion; scar tissue may form at an implanted stent; and, other complications (e.g. acute myocardial infarction (AMI), stroke) can occur. This editorial addresses changing paradigms and perceptions in the treatment of CAD, with specific reference to atherosclerosis and the triggering of AMI, conventional risk factors, limitations of coronary angiography, the use (or abuse) of cardiac procedures, medical therapy versus coronary angioplasty, and the value of comprehensive cardiovascular risk reduction.
Atherosclerosis and acute myocardial infarction: the new view
Investigations begun more than 25 years ago have now refuted the traditional view of atherosclerosis: that over time, cholesterol simply builds up on passive artery walls. It appears that arterial inflammation plays a key role in the development and progression of atherosclerosis, which can be triggered by excess low-density lipoprotein (LDL)-cholesterol. This new view highlights the importance of assessing inflammatory markers (e.g. C-reactive protein) and providing interventions to reduce risk factors that may exacerbate arterial inflammation [1] .
Numerous studies indicate that AMIs often evolve from mild-to-moderate coronary artery stenoses. In a study of patients who had undergone cardiac catheterization before and up to 1 month after AMI, the coronary artery that subsequently occluded had less than 50% stenosis on the first angiogram in 19 of 29 patients (66%) [2] . Subsequently, these investigators reported that occlusion of unbypassed arteries that did not previously contain angiographically apparent obstructive stenoses may be an important cause of AMI after CABG surgery [3] . More recently, Falk et al. [4] , consolidating the data from four separate studies, demonstrated that the vast majority of AMIs involve sites with under 70% obstruction in the months to years before infarction ( Fig. 1 ). Collectively, these findings suggest a new paradigm for preventing and managing CAD (Table 1) [5] , and explain the inability to demonstrate a reduction in cardiovascular events in most studies examining CABG surgery or PCI.
Risk factors for coronary heart disease: debunking an old myth
Two landmark studies [6, 7] now challenge the traditional notion that approximately 50% of cardiac events occur in patients without any of the major conventional coronary risk factors: diabetes, cigarette smoking, hyperlipidemia, and hypertension. In an analysis of data from three prospective cohort studies (n ¼ 20 995), Greenland et al. [6] reported that 87-100% of patients who experienced a fatal cardiac event had antecedent exposure to one or more major coronary risk factors. Khot et al. [7] analyzed data from patients with heart disease enrolled in 14 international randomized clinical trials (n ¼ 122 458) and, similarly, found at least one of the four conventional risk factors in this cohort. Although an accompanying editorial [8] urged physicians to increase efforts to favorably modify conventional coronary risk factors in their patients, a just-published study [9] , using a large, international contemporary database, reported that classic cardiovascular risk factors are consistent and common and remain largely undertreated and undercontrolled in many regions of the world.
Limitations of angiography in evaluating atherosclerotic coronary disease
The escalating reliance on coronary revascularization treatments for CAD, that is, either PCI or CABG surgery, is primarily attributed to data derived from conventional coronary angiography. Angiographic findings may be misleading, however, by presenting coronary disease as a focal process. A classic report [10] demonstrated that the coronary artery enlarges in association with plaque accumulation to maintain an adequate, if not normal, lumen area ( Fig. 2 ). Moreover, it appears that coronary angiography detects only the severest of coronary narrowings [11] . Intracoronary ultrasound reinforces this observation, since the angiogram and ultrasound studies can be performed simultaneously [12] .
A study of 884 angiographically normal coronary segments in patients with coronary stenoses elsewhere found that only 60 (6.7%) of these segments were judged normal by intracoronary ultrasound [13] . Indeed, the average crosssectional narrowing of these 'angiographically normal' segments was 51% by ultrasound criteria. Because most coronary lesions that trigger an AMI have an under 50% diameter stenosis on previous angiography [2, 4] , and thus are not targets for revascularization, it explains the futility of this approach in attempting to prevent acute coronary events.
Overtreating patients with invasive cardiac procedures?
Approximately 1.6 million US adults undergo CABG surgery or PCI/stenting procedures annually. Worldwide, more than 1 million patients undergo coronary angioplasty each year. Nevertheless, several recent studies suggest that many of these costly procedures are probably unnecessary, and not without risk (e.g. AMI, stroke, cognitive difficulties). Others emphasize that the survival rate for stable patients who undergo these procedures, many of which are repeats, is almost exactly the same as it is for patients with heart disease who are medically managed.
Tu et al. [14] compared the medical outcomes of more than 230 000 elderly patients in the US and Canada, each of whom had a recent AMI. The US patients were Stenosis severity and risk of associated myocardial infarction. Nearly 90% of acute myocardial infarctions (AMIs) occur at sites without a significant stenosis (o70% obstruction) on a previous angiogram. Rupture of a vulnerable atherosclerotic plaque, characterized by a thin fibrous cap and a large low-density lipoprotein (LDL)-cholesterol laden lipid core, is believed to be the triggering mechanism underlying rapid progression of mild-to-moderate lesions to severe stenosis or total coronary artery occlusion. Data from Falk et al. [4] . Possible sequence of atherosclerotic disease progression in a coronary artery leading eventually to lumen narrowing. The artery enlarges initially (left to right in diagram) in relation to plaque accumulation. Functionally important lumen stenosis may be delayed until the lesion occupies approximately 40% of the internal elastic lamina area, indicating that plaque size or the extent of atherosclerotic coronary artery disease may be greatly underestimated when only the lumen is visualized. Data from Glagov et al. [10] . significantly (Po0.001) more likely than the Canadian patients to undergo coronary angiography (34.9% versus 6.7%), PCI (11.7% versus 1.5%), and CABG surgery (10.6% versus 1.4%) during the first 30 days after the index infarction, yet both groups had exactly the same survival rates 1 year later. The investigators concluded that the greater use of revascularization procedures in the US does not improve the long-term survival rates of elderly US patients with AMI. Similarly, de Winter et al. [15] were unable to demonstrate that an early invasive strategy was superior to a selectively invasive strategy in patients with acute coronary syndromes and an elevated cardiac troponin T level, but without ST-segment elevation. Moreover, the incidence of AMI was significantly higher in the early-invasive-strategy group, particularly during hospitalization, confirming a previous report that acute coronary events may occur during early revascularization [16] .
Medical therapy versus coronary angioplasty
A recent review [17] of the contemporary literature regarding the use of medical therapy versus PCI in patients with stable CAD suggests the following conclusions: K The prognosis for patients with single-vessel CAD and good left ventricular function is generally favorable, and PCI of a significant stenoses (470% obstruction) does not reduce the rate of subsequent AMI or mortality.
K PCI results in superior symptomatic relief of angina and improved exercise tolerance compared with medical therapy [18] .
K The benefits of PCI may be greater in patients with a high-grade stenoses of the proximal left anterior descending coronary artery, as compared with medical therapy.
K The salutary effects of PCI in some patients may be countered, at least in part, by a higher risk of procedural complications (e.g. AMI, emergent CABG surgery).
Although all comparative studies to date have had significant methodologic deficiencies [17] , the Atorvastatin Versus Revascularization Treatment (AVERT) study [19] rekindled the debate concerning the preferred therapeutic strategy in patients with stable single or double vessel CAD. After 18 months' follow-up, 22 of the 164 patients (13%) receiving atorvastatin had an ischemic event compared with 37 of 177 (21%) assigned to angioplasty and usual care, signifying a 36% reduction (P ¼ 0.048) in the group that received aggressive lipidlowering therapy. Nevertheless, these results are not necessarily generalizable to large numbers of patients who presently undergo even more effective techniques in revascularization (e.g. the use of stents and glycoprotein IIb/IIIa inhibitors to reduce restenosis and ischemic complications) [20] .
Recently, Katritsis and Ioannidis [21] performed a metaanalysis of 11 randomized trials comparing PCI with conservative treatment in patients with stable CAD. There was no significant difference between the two treatment strategies for any of the outcome variables tested (Fig. 3) ; if anything, there was a trend for more cardiac deaths or AMIs, particularly nonfatal AMIs, in patients who underwent PCI. By comparing the benefits, if any, against cost considerations and complications, the investigators concluded that many PCIs that are currently performed in patients with nonacute CAD are probably not justified.
COURAGE (Clinical Outcomes Utilizing
Revascularization and Aggressive DruG Evaluation) is a multi-center, randomized, controlled clinical trial designed to compare the effectiveness of intensive and multi-faceted medical therapy to PCI combined with intensive medical therapy [22] . The first patient was enrolled in June 1999; thus, the investigators now have 2.5-to 7-year (median of 5 years) follow-up on 2287 patients with angiographically confirmed CAD. Of note, the Data Safety Monitoring Board met every 9 months throughout the trial (follow-up concluded in June 2006) and did not stop the trial prematurely (something most believed would happen). This strongly suggests that PCI plus intensive medical therapy may not differ appreciably from intensive medical therapy alone for the trial primary endpoint of all-cause mortality or AMI. 
Favors PCI Favors medical treatment
Meta-analysis of 11 randomized clinical trials comparing percutaneous coronary intervention to conservative medical treatment in patients with stable coronary artery disease. Comparisons for death, cardiac death or acute myocardial infarction (AMI), nonfatal AMI, coronary artery bypass graft (CABG) surgery, and percutaneous coronary intervention (PCI) during follow-up, with specific reference to the summary risk ratio and 95% confidence intervals (CI). Data from Katritsis and Ioannidis [21] .
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Comprehensive cardiovascular risk reduction
Contemporary studies now suggest that multifactorial risk-factor modification -especially smoking cessation [23] and more intensive measures to control hyperlipidemia with diet, drugs, and exercise -may slow, halt, or even reverse (Fig. 4 ) the otherwise inexorable progression of atherosclerotic CAD [24, 25] . Early and continued lowering of LDL-cholesterol to values substantially below recent target levels, that is, approximating 60 mg/dl, has been shown to benefit patients with acute coronary syndromes [26] [27] [28] . Moreover, an initial trial of an exogenously produced high-density lipoprotein (HDL) cholesterol mimetic, an ApoA-1-Milano/phospholipid complex, demonstrated significant and rapid regression of atherosclerosis by intravascular ultrasound [29] .
Recently, Chiuve et al. [30] demonstrated that a healthy lifestyle plays an important role in the primary prevention of heart disease in middle-aged and older men, even among those taking medications for hypertension or hypercholesterolemia. Moreover, effect estimates show convincingly the health benefits of lifestyle changes in patients with CAD, the magnitude of which are similar to those reported with preventive drug interventions after myocardial infarction (Table 2 ) [31, 32] . Collectively, these findings and other recent data suggest that the effects of lifestyle change and combination drug therapy on cardiovascular risk reduction appear to be independent and additive [33] [34] [35] [36] .
The benefits of aggressive risk factor modification include a reduction in anginal symptoms, decreases in exercise-induced ischemic ST-segment depression, fewer recurrent cardiac events, and a diminished need for PCI or CABG surgery. Several mechanisms may contribute to these improved clinical outcomes, including partial (albeit small) anatomic regression of coronary artery stenoses, improved coronary artery vasomotor function, and a reduced incidence of plaque rupture [37] . The latter may be especially cardioprotective, because AMI in medically treated patients with CAD frequently occurs at sites without a significant stenosis on a previous angiogram [2, 4] .
Conclusion
The treatment of CAD has evolved from simple lifestyle modification in the mid-to-late 1960s, largely focused on early ambulation, exercise training, and a prudent diet, to an array of costly and palliative coronary revascularization procedures (Fig. 5 ) that are not without risk and, unfortunately, fail to address the underlying causes: high-fat and cholesterol diets, cigarette smoking, hypertension, obesity, and physical inactivity [37] . Aggressive risk-factor reduction, including lifestyle modification and complementary pharmacotherapies, however, can Lumen
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Possible mechanism of plaque regression. Left, coronary artery that is narrowed 475% in cross-sectional area by atherosclerotic plaque.
Although it is unlikely that fibrous tissue is reversible, the lipid portion may shrink if serum total and low-density lipoprotein (LDL) cholesterol levels are substantially reduced, high-density lipoprotein (HDL) cholesterol levels are markedly increased, or both. Because coronary blood flow is usually not significantly impaired until the obstruction reaches 75% of the vessel's cross-sectional area, small reductions in plaque mass may lead to large increases in lumen size and coronary blood flow, as is shown in the right portion of diagram. Data from Roberts [25] . Recent studies suggest that each one metabolic equivalent (MET; 1 MET ¼ 3.5 mlO 2 /kg per min) increase in exercise capacity appears to confer an 8-17% reduction in mortality [5] . Alternatively, an approximate 1000 kcal/week increase in activity confers the equivalent survival benefit that would accrue by increasing fitness by 1 MET [32] . Data from Iestra et al. [31] . 
Coronary Thrombolysis
Evolutionary treatment of coronary artery disease since the 1960s. Although coronary revascularization and aggressive medical treatment (lifestyle modification and pharmacotherapies) should be used synergistically, these differing therapeutic approaches are often overutilized and underemphasized, respectively. stabilize and even reverse the atherosclerotic process. Many of these interventions are applicable to primary and secondary prevention and are individually associated with a remarkably consistent mortality risk reduction (approximately 18-45%; Table 2 ) in patients with known heart disease [31] . When selectively combined, even greater reductions in morbidity and mortality are likely to be achieved.
